S eptic shock is a heterogeneous syndrome with variable physiological and biologic manifestations across patient groups (1, 2) . A major challenge in critical care medicine is the development of clinically feasible stratification strategies to manage this heterogeneity for the design of more effective clinical trials and individ-ualized patient management (3, 4) . We are addressing the challenge of septic shock heterogeneity by leveraging the discovery potential of whole-genome expression profiling (5) .
Viewing septic shock as a syndrome implies the existence of septic shock subclasses predicated on distinct biologic processes leading to distinct clinical phenotypes. We previously identified three putative subclasses of children with septic shock based exclusively on differential gene expression patterns representing the first 24 hrs of admission to the pediatric intensive care unit (PICU) (6) . Further analyses of the subclasses revealed important phenotypic differences, thus suggesting that the gene expression-based subclasses are clinically relevant. In a subsequent crossvalidation study, we demonstrated that clinicians could reliably assign patients to the putative subclasses based on 100 classdefining genes depicted as visually intuitive gene expression mosaics (7) .
We now seek to prospectively validate our subclassification strategy in a new cohort of children with septic shock. We test the hypothesis that the differential expression patterns of 100 class-defining genes, depicted using visually intuitive expression mosaics, can be used to allocate a validation cohort into septic shock subclasses having relevant clinical differ-Objective: Septic shock heterogeneity has important implications for clinical trial implementation and patient management. We previously addressed this heterogeneity by identifying three putative subclasses of children with septic shock based exclusively on a 100-gene expression signature. Here we attempted to prospectively validate the existence of these gene expressionbased subclasses in a validation cohort.
Design: Prospective observational study involving microarraybased bioinformatics.
Setting: Multiple pediatric intensive care units in the United States.
Patients: Separate derivation (n ‫؍‬ 98) and validation (n ‫؍‬ 82) cohorts of children with septic shock.
Interventions: None other than standard care. Measurements and Main Results: Gene expression mosaics of the 100 class-defining genes were generated for 82 individual patients in the validation cohort. Using computer-based image analysis, patients were classified into one of three subclasses ("A," "B," or "C") based on color and pattern similarity relative to reference mosaics generated from the original derivation cohort. After subclassification, the clinical database was mined for phenotyping. Subclass A patients had higher illness severity relative to subclasses B and C as measured by maximal organ failure, fewer intensive care unit-free days, and a higher Pediatric Risk of Mortality score. Patients in subclass A were characterized by repression of genes corresponding to adaptive immunity and glucocorticoid receptor signaling. Separate subclass assignments were conducted by 21 individual clinicians using visual inspection. The consensus classification of the clinicians had modest agreement with the computer algorithm.
Conclusions: We have validated the existence of subclasses of children with septic shock based on a biologically relevant, 100gene expression signature. 
METHODS
Patients and Data Collection. The study protocol was approved by the institutional review boards of each institution (n ϭ 11) and is identical for both the derivation and validation cohorts. Children Յ10 yrs of age admitted to the PICU and meeting pediatric-specific criteria for septic shock were eligible (8) . Control subjects were recruited from the ambulatory departments of participating institutions using published inclusion and exclusion criteria (9, 10) . The derivation cohort of 98 patients with septic shock and 32 normal control subjects was previously published (6, 7) . The validation cohort consists of 82 new patients with septic shock and 21 new control subjects (control median age 2.9 yrs [1.3-5.6]; 11 males and ten females). The microarray data for both cohorts have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (accession numbers GSE26440 and GSE26378).
After informed consent from parents or legal guardians, blood samples were obtained within 24 hrs of initial presentation to the PICU with septic shock. Clinical and laboratory data were collected daily while in the PICU and stored using a Web-based database.
The following variables were tracked as indicators of illness severity: organ failure, Pediatric Risk of Mortality (PRISM) score (11), PICU-free days, and mortality. Organ failure was defined using pediatric-specific criteria and tracked up to the first 7 days of PICU admission (8) . The calculation of PICU-free days was based on the difference between a maximum PICU admission of 28 days and the actual PICU days. Patients who died during the 28-day study period and patients that remained in the PICU for Ն28 days were assigned zero PICU-free days. Mortality was tracked for 28 days after enrollment.
RNA Extraction and Microarray Hybridization. Total RNA was isolated from whole blood using the PaxGene Blood RNA System (PreAnalytiX; Qiagen/Becton Dickson, Valencia, CA). Microarray hybridization was performed as previously described using the Human Genome U133 Plus 2.0 GeneChip (Affymetrix, Santa Clara, CA) (6, 9, 10, (12) (13) (14) . CEL files were preprocessed using Robust Multiple-Array Average normalization and GeneSpring GX 7.3 software (Agilent Technologies, Palo Alto, CA). All signal intensity-based data were used after Robust Multiple-Array Average normalization (15) . All chips were normalized to the respective median values of control subjects.
Gene Expression Mosaics. In the aforementioned study (the derivation cohort), we used discovery-oriented expression and statistical gene filters and unsupervised hierarchical clustering to identify three putative sub-classes of children with septic shock (subclasses "A," "B," and "C") (6) . We subsequently refined the subclass-defining signature to 100 genes using a two-stage approach. In stage 1, we used K-means clustering to identify coordinately regulated gene clusters corresponding to signaling pathways related to inflammation and immunity. In stage 2, we tested the genes identified in stage 1 for the ability to predict the putative subclass and extracted the top 100 class-predictor genes (6) . These 100 class-predictor genes form the basis of the current study (see Supplemental Expression mosaics representing the 100 class-defining genes were generated using the Gene Expression Dynamics Inspector (16, 17) . The signature graphical outputs of Gene Expression Dynamics Inspector are expression mosaics that give microarray data a "face" that is intuitively recognizable through human pattern recognition. The algorithm for creating the mosaics is a self-organizing map. Additional technical details regarding Gene Expression Dynamics Inspector can be found at: http://www.childrenshospital.org/research/ ingber/GEDI/gedihome.htm.
Computer-Based Classification. The reference mosaics representing the 100 classdefining genes are published (7) and represent the average expression patterns of the individual patients within a given subclass of the derivation cohort. For each patient in the validation cohort, the respective expression data for the 100 class-defining genes were uploaded to Gene Expression Dynamics Inspector and individual expression mosaics were generated for each patient. Validation cohort patients were then subclassified using a public image analysis platform (ImageJ, http://rsbweb. nih.gov/ij/). The reference and the individual patient mosaics from the validation group were loaded onto ImageJ. The absolute difference in RGB pixel-to-pixel intensity was calculated for each individual patient mosaic in the validation cohort relative to each of the three reference mosaics. Final subclassification was based on the "least difference" between the individual patient mosaic and one of the three reference mosaics.
Clinician-Based Subclassification. We also conducted clinician-based subclassification as previously described (7) . Twenty-one pediatric intensivists participated as evaluators. Each evaluator was shown the 82 individual patient mosaics from the validation cohort and asked to classify each patient as subclass "A," "B," or "C" based on color and pattern similarity relative to the reference mosaics. The clinicians were not provided with any additional instructions and were blinded to clinical data. Clinician responses were catalogued and subsequently used to arrive at a final consensus subclassification based on the "majority call" (i.e., eight or more calls for a given class).
Clinical Phenotyping and Data Analysis.
After the patients in the validation cohort were subclassified, we mined the clinical database to assess clinical differences among the three subclasses. Ordinal and continuous clinical variables not normally distributed were analyzed through three-group analysis of variance on ranks. Dichotomous clinical variables were analyzed using a two-by-three contingency table and chi-square test (SigmaStat Software; Systat Software, Inc, San Jose, CA).
RESULTS
Baseline Data. The characteristics of the derivation and validation cohorts are provided in Table 1 . The validation cohort had a higher proportion of males, a lower proportion of patients with immune suppression, and a lower proportion of patients with negative microbiologic cultures compared with the derivation cohort. All other variables in Table 1 were not significantly different between the two cohorts.
The reference mosaics for the subclassification protocol are shown in the upper panel of Figure 1 . The reference mosaics depict the average expression patterns of the same 100 class-defining genes and represent the three previously published derivation cohort septic shock subclasses (6, 7) . Examples of individual patient mosaics in the validation cohort, representing the same 100 class-defining genes, are shown in the lower panel of Figure 1 .
Computer-Based Subclassification. Table 2 provides the characteristics of the validation cohort subclasses based on the computer algorithm. Subclass A patients had higher illness severity than subclass B and C patients as measured by maximum number of organ failures and PRISM scores. Subclass A patients also had higher illness severity than subclass B patients, as measured by fewer PICU-free days. There was a trend toward a higher mortality odds ratio in subclass A patients relative to subclass B and C patients. Subclass A patients were also younger and had a lower peripheral total white blood cell count and neutrophil count compared with subclass B patients. All other variables in Table 2 were not significantly different across the three septic shock subclasses in the validation cohort. These data demonstrate that computer-based image analysis can allocate patients into gene expression-based septic shock subclasses having relevant clinical differences.
Clinician-Based Subclassification. In this analysis, the clinical evaluators con-ducted the subclassification as described in the "Methods." For 31 of the validation cohort patients (38%), all 21 evaluators provided the same subclassification. The other potential majority calls (ranging from 8 to 20) were relatively evenly distributed (Fig. 2) . Four patients received Ͻ11 majority calls (i.e., Ͻ50% of the evaluators agreed to the same classification). The individual expression mosaics of these four patients and their respective 28-day outcomes are provided in Figure 3 .
The coefficient to measure interevaluator agreement among the 21 evaluators was 0.633 (0 ϭ no agreement; 1 ϭ perfect agreement). Sixty-five of the validation cohort patients (79%) were allocated to the same subclass by both the computer algorithm and the consensus classification generated by the clinicians ( coefficient ϭ 0.688). Table 3 provides the characteristics of the validation cohort subclasses based on the consensus classification of the 21 clinicians. Subclass A patients had higher illness severity than subclass B and C patients as measured by maximum number of organ failures and PRISM score. Subclass A patients were also younger and had a lower peripheral total white blood cell count and neutrophil count compared with subclass B patients. All other variables in Table 3 were not significantly different across the three septic shock subclasses in the validation cohort. These data validate that clinicians can allocate patients with septic shock into gene expressionbased subclasses having relevant clinical differences.
Clinical Characteristics of the Combined Cohorts. Combined with our previous report (6), we have allocated a total of 180 patients into expression-based subclasses. The major clinical characteristics of the respective subclasses are consistent when comparing the current validation cohort and the original derivation cohort (6) . Table 4 provides the major clinical differences among the three subclasses in this combined cohort. Subclass A patients have a significantly higher mortality rate and mortality odds ratio than patients in subclasses B and C. Subclass A patients also have a higher number of organ failures, a higher PRISM score, and fewer PICU-free days than patients in subclasses B and C. Finally, subclass B patients are older and have a higher proportion of females compared with subclasses A and C.
Addressing Potential Confounding Variables. Because we used whole bloodderived RNA, it is possible that the classdefining gene expression patterns reflect differential white blood cell counts. Accordingly, we analyzed our expression data for the presence of previously published signature probe sets for neutrophils, lymphocytes, and monocytes, respectively (18) . Signature probe "presence" was defined using the following criteria: Ն100 raw expression value in a least half of the subjects in each subclass. Table 5 provides the results from this analysis and demonstrates that the signature probe sets were equally present across the three subclasses. Thus, the relative contributions of the three major leukocyte subsets, to the whole blood transcriptomic response, were relatively similar across the three subclasses. Accordingly, the differences in gene expression among the three subclasses do not appear to be artifacts of differential peripheral white blood cell counts.
The validation cohort had a significantly lower proportion of patients with negative cultures compared with the derivation cohort. Accordingly, we conducted a two-group analysis of variance (Benjamini-Hochberg false discovery rate ϭ 5%) to determine whether the 100 class-defining genes were differentially expressed between patients with negative cultures (n ϭ 25) and patients with positive cultures (n ϭ 57) in the validation cohort. This analysis revealed that none of the 100 subclass-defining genes were differentially expressed between the two groups, thus suggesting that microbiology culture status was unlikely to be a strong confounder. IQR, interquartile range. a Continuous variables are analyzed by analysis of variance on ranks and proportions are analyzed by chi square; b the maximum number of organ failures during the initial 7 days of pediatric intensive care unit admission; c patients having any major diagnosis in addition to septic shock (e.g., trauma, sickle cell disease, congenital heart disease, liver failure, etc.); d patients with immune deficiency secondary to an intrinsic documented defect of the immune system, or patients receiving immunesuppressive medications (e.g., calcineurin inhibitors or high-dose corticosteroids); e for cardiovascular shock; f all bacterial culture data refer to samples obtained from bodily fluids that are normally sterile (i.e., blood, urine, cerebral spinal fluid, bronchoalveolar lavage, and/or peritoneal fluid).
The validation cohort also had a higher proportion of males compared with the derivation cohort. Accordingly, we conducted a two-group analysis of variance (Benjamini-Hochberg false discovery rate ϭ 5%) to determine whether the 100 class-defining genes were differentially expressed between males (n ϭ 57) and females (n ϭ 25) in the validation cohort. This analysis revealed that none of the 100 subclass-defining genes were differentially expressed between males and females, thus suggesting that gender was unlikely to be a strong confounder.
Because patients were recruited from multiple centers, it is possible that center-specific effects could confound the data. Table 6 provides the number of validation cohort patients in each gene expression-based subclass based on enrollment site. Thirty-seven patients (45%) in the validation cohort were recruited from site 1. Also, site 1 contributed a smaller proportion of subclass A patients compared with subclass C patients. There were no other significant differences regarding enrollment among the other sites. Thus, we cannot rule out the possibility that the data are confounded, in part, by center-specific effects.
DISCUSSION
A systematic review by Tang et al (19) of microarray-based expression profiling studies in human sepsis was recently conducted. One conclusion from this review is that the transcriptomic response is highly variable in human sepsis. Our previous data are consistent with this conclusion by demonstrating the potential existence of three subclasses of children with septic shock as defined by variable gene expression. We have now prospectively validated that a 100-gene expression signature, depicted using visually intuitive mosaics, can be used to allocate patients with septic shock into subclasses having clinically relevant phenotypic differences and biologically relevant differential gene expression. Although the subclassification strategy needs to be further refined, and one would expect that computer-based subclassification would be superior to that of clinician-based subclassification, we have nonetheless demonstrated that clinically relevant subclasses of children with septic shock can be identified through gene expression profiling.
The assertion that the subclasses have clinically relevant phenotypes is based on IQR, interquartile range. a Continuous variables are analyzed as three-group comparisons using analysis of variance on ranks and 2 degrees of freedom. Proportions are analyzed as three-group comparisons using a two-by-three contingency table and chi square with 2 degrees of freedom; b odds ratio for mortality vs. subclass B: 3.1 (0.6 -17.3), vs. subclass C: 1.9 (0.5-7.7); c the maximum number of organ failures during the initial 7 days of pediatric intensive care unit admission; d patients having any major diagnosis in addition to septic shock (e.g., trauma, sickle cell disease, congenital heart disease, liver failure, etc.); e patients with immune deficiency secondary to an intrinsic documented defect of the immune system, or patients receiving immune-suppressive medications (e.g., calcineurin inhibitors or high-dose steroids); f for cardiovascular shock; g all bacterial culture data refer to samples obtained from bodily fluids that are normally sterile (i.e., blood, urine, cerebrospinal fluid, bronchoalveolar lavage, and/or peritoneal fluid). a higher level of illness severity in the subclass A patients as measured by mortality, maximal number of organ failures, PRISM scores, and PICU-free days. The profound negative impact of multiple or-gan failure on outcomes in critical illness is well established (20 -22) and is therefore a clinically relevant measure. The reliance on PRISM scores could lead one to conclude that it would be more straightforward to calculate PRISM scores as a means of stratification. However, illness severity scores such as PRISM and Acute Physiology and Chronic Health Evaluation are intended for population-based predictions rather than for individual patient stratification and do not provide biological information (23) .
Patients in validation cohort subclass A had a trend toward higher mortality, which did not reach statistical significance. However, when we combined both the derivation and validation cohorts, the subclass A patients have a significantly higher mortality rate. Notably, the mortality rates of the patients in subclasses B and C are consistent with current estimates for the United States (24 -26) , whereas the mortality rate in subclass A patients is threefold higher.
The assertion that the subclasses have biologically relevant differences in gene expression is based on the functional significance of the 100 class-defining genes, which are enriched for genes corresponding to adaptive immunity (6, 27) . The majority of these genes corresponding to adaptive immunity are repressed in subclass A patients relative to subclass B and C patients (6) . It is unlikely that lymphopenia accounts for this observation because the absolute lymphocyte counts were not significantly different among the three subclasses. Recent literature indicates that enhancement of adaptive immune function may be a rational therapeutic strategy in sepsis (28 -33) . Optimization of such a strategy, however, will need to take into account the potential existence of subclass A patients characterized by a higher illness severity and repression of adaptive immunity-related genes.
The 100 class-defining genes are also enriched for genes corresponding to glucocorticoid receptor signaling (6, 27) , and these genes are also repressed in subclass A patients relative to subclass B and C patients (6) . Glucocorticoid replacement therapy and the concept of relative adrenal insufficiency in septic shock are highly controversial topics in critical care medicine (34 -36) . The potential existence of a subclass of patients with septic shock (i.e., subclass A) having a higher illness severity and repression of genes corresponding glucocorticoid receptor signaling may have important implications for future clinical trials and may have been confounders in previous clinical trials. IQR, interquartile range. a Continuous variables are analyzed as three-group comparisons using analysis of variance on ranks and 2 degrees of freedom. Proportions are analyzed as three-group comparisons using a two-by-three contingency table and chi square with 2 degrees of freedom; b odds ratio for mortality vs. subclass B: 1.5 (0.4 -4.6), vs. subclass C: 2.2 (0.5-10.2); c the maximum number of organ failures during the initial 7 days of pediatric intensive care unit admission; d patients having any major diagnosis in addition to septic shock (e.g., trauma, sickle cell disease, congenital heart disease, liver failure, etc.); e patients with immune deficiency secondary to an intrinsic documented defect of the immune system, or patients receiving immune-suppressive medications (e.g., calcineurin inhibitors or high-dose steroids); f for cardiovascular shock; g all bacterial culture data refer to samples obtained from bodily fluids that are normally sterile (i.e., blood, urine, cerebrospinal fluid, bronchoalveolar lavage, and/or peritoneal fluid). (16) (17) (18) (19) (20) (21) (22) (23) (24) .002 IQR, interquartile range. a Continuous variables are analyzed as three-group comparisons using analysis of variance on ranks and 2 degrees of freedom. Proportions are analyzed as three-group comparisons using a two-by-three contingency table and chi square with 2 degrees of freedom; b odds ratio for mortality vs. subclass B: 3.6 (1.4 -9.6), p ϭ .007, vs. subclass C: 2.9 (1.1-7.7), p ϭ .03. Subclass A patients were significantly younger than subclass B patients in both our previous study (6) and the current study. This observation is consistent with pediatric septic shock epidemiology, which has identified young age as a risk factor for increased illness severity (24 -26) . However, subclass C patients are of a similar age to subclass A patients but have a lower illness severity in both studies. Thus, although younger age is a risk factor for illness severity, the current data indicate that the expression pattern of the 100 class-defining genes also impacts illness severity, independent of age.
Our subclassification strategy is focused on a single time point and therefore does not take into account potential temporal shifts in patient status from one subclass to another. However, the major goal of the strategy is to allocate patients into subclasses at a time point that affords earlier clinical management decisions or early stratification for clinical trials (4, 37, 38) .
In conclusion, we have addressed the challenges of septic shock heterogeneity and stratification by prospectively validating the existence of septic shock subclasses based on a 100-gene expression signature. The subclasses can be identified at a clinically relevant time point and have relevant clinical differences. Finally, the expression patterns of the 100 class-defining genes may have therapeutic implications. 11  18  37  Site 2  2  1  1  4  Site 3  1  1  4  6  Site 4  1  3  0  4  Site 5  4  4  2  10  Site 6  3  0  1  4  Site 7  1  1  2  4  Site 8  1  0  0  1  Site 9  3  0  1  4  Site 10  2  1  1  4  Site 11  1  2 1 4 a p Ͻ .05 vs. subclass C (chi square with 2 degrees of freedom).
